Illumina Inc. Stock Underperforms Tuesday When Compared To Competitors

Eton Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

ETON Eton Pharmaceuticals Inc

LXRX Lexicon Pharmaceuticals Inc

BVS Bioventus Inc

TDS-U Telephone and Data Systems Inc

ELEV Elevation Oncology Inc

FRZA Forza X1 Inc

SIEN Sientra Inc

PMGM Priveterra Acquisition Corp

NVFY Nova LifeStyle Inc

GGIFF Garibaldi Resources Corp

Health Care : Pharmaceuticals | Small Cap Blend

Company profile

Eton Pharmaceuticals, Inc. is a pharmaceutical company, which is developing, acquiring and commercializing products to address unmet needs in patients suffering from rare diseases. It has three commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase deficiency, and Betaine Anhydrous for the treatment of homocystinuria. It also has three additional product candidates in late-stage development. The Company is developing dehydrated alcohol injection, which has received Orphan Drug Designation for the treatment of methanol poisoning, ZENEO hydrocortisone autoinjector for the treatment of adrenal crisis, and ET-400. Its dehydrated alcohol injection product candidate is under review for the treatment of methanol poisoning. Its ZENEO hydrocortisone autoinjector product candidate is a needle-free autoinjector under development for the treatment of adrenal crisis.

Illumina Inc. Stock Underperforms Tuesday When Compared To Competitors

5:02 pm ET February 21, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Illumina Inc. (ILMN) slipped 4.24% to $202.84 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 2.00% to 3,997.34 and Dow Jones Industrial Average falling 2.06% to 33,129.59. Illumina Inc. closed $168.32 short of its 52-week high ($371.16), which the company achieved on April 4th.

The stock underperformed when compared to some of its competitors Tuesday, as Laboratory Corp. of America Holdings (LH) fell 3.49% to $247.32, Charles River Laboratories International Inc. (CRL) fell 2.47% to $243.60, and Quest Diagnostics Inc. (DGX) fell 3.13% to $143.58. Trading volume (1.8 M) eclipsed its 50-day average volume of 1.3 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 21, 2023.

(END) Dow Jones Newswires

February 21, 2023 17:02 ET (22:02 GMT)